Chronic Leukemias

Chronic Leukemias

A collection of features and news articles published in ASH Clinical News related to chronic leukemias.

Asciminib Shows Durable Clinical Activity in Heavily Pretreated CML

In a phase I, dose-escalation study, treatment with asciminib was active and associated with durable responses in more than half of patients with chronic...

Defining the Goals of Venetoclax Treatment in Relapsed/Refractory CLL

Achieving undetectable measurable residual disease (MRD) predicts a better clinical outcome in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) who are treated with venetoclax,...

Study Finds Higher Rates of Leukemia in 9/11 Responders and Recovery Workers

Investigators  discovered an increase in the incidence of leukemia in first responders and other recovery workers who were at the World Trade Center (WTC)...

Acalabrutinib Approved for CLL Under New International Collaboration

The FDA granted a supplemental approval to acalabrutinib for the treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Acalabrutinib...

Perspectives on 2019’s New Hematology Drug Approvals

In 2019, the FDA approved several new therapies – or new indications for previously approved therapies – for people living with blood disorders, including...

Time-Limited Acalabrutinib Combination Has “Encouraging” Response Rates in Previously Untreated Chronic Lymphocytic Leukemia

Watch our interview with Benjamin Lampson, MD. Preliminary results from a trial presented at the 2019 ASH Annual Meeting suggest that time-limited frontline therapy for...

Constantine Tam: Zanubrutinib Active in Treatment-Naïve CLL/SLL

Constantine S. Tam, MBBS, MD, discusses findings from the phase III SEQUOIA trial, in which 92% of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma...

Benjamin Lampson: Acalabrutinib Combo Leads to Deep, Durable Responses in Frontline CLL

Nearly half of patients treated with acalabrutinib plus venetoclax and obinutuzumab achieved a complete response with undetectable minimal residual disease. Benjamin L. Lampson, MD,...

Study Examines Trends in Real-World Treatment Sequencing Patterns for CLL

The availability of B-cell receptor inhibitors (BCRis) and other novel agents for the treatment of chronic lymphocytic leukemia (CLL) has reshaped the treatment paradigm...
You Make the Call

How would you treat a patient with CLL who developed warm autoimmune hemolytic anemia?

This month, Dr. Jacobsen discusses how to treat a patient with chronic lymphocytic leukemia who develops warm autoimmune hemolytic anemia. And don't forget to check...
Advertisement

Current Issue

August 2020 Volume 6, Issue 10

This issue looks at the rapid expansion of telemedicine, explores access to leukemia treatment in Brazil, and more.

Block title